What is the recommended pneumococcal vaccination schedule for adults aged 65 years and older, including the 13‑valent pneumococcal conjugate vaccine (PCV13) and the 23‑valent pneumococcal polysaccharide vaccine (PPSV23)?

Pneumococcal Vaccination for Elderly Adults

All adults aged ≥65 years should receive pneumococcal vaccination, with the most current 2023 ACIP guidelines recommending either a single dose of PCV20 OR a sequential regimen of PCV15 followed by PPSV23, based on vaccine availability and patient-specific risk factors 1.

Current Recommendations (2023 ACIP Guidelines)

The 2023 guidelines represent a significant update from previous recommendations, offering two distinct vaccination pathways:

For Immunocompetent Adults ≥65 Years (No High-Risk Conditions)

Option A (Preferred if PCV20 available):

• Single dose of PCV20 1
• This is the simplest approach, providing comprehensive coverage with one injection

Option B (If PCV15 and PPSV23 available):

• PCV15 first, then PPSV23 ≥1 year later 1
• The extended interval allows for optimal immune response

For High-Risk Adults ≥65 Years

High-risk conditions include immunocompromising conditions (chronic renal failure, immunodeficiency, HIV, malignancy, iatrogenic immunosuppression, asplenia, sickle cell disease, nephrotic syndrome, solid organ transplant), CSF leak, or cochlear implant 1.

Vaccination schedule:

• PCV15 first, then PPSV23 ≥8 weeks later (shortened interval for faster protection) 1
• The accelerated schedule reflects the urgent need for protection in immunocompromised individuals

Previously Vaccinated Adults: What to Do

If Previously Received PPSV23 Only

• Give PCV20 ≥1 year after last PPSV23 dose (Option A) 1
• OR give PCV15 ≥1 year after last PPSV23 dose (Option B) 1

If Previously Received PCV13 Only

• Give PCV20 ≥1 year after PCV13 (for immunocompetent) 1
• OR give PPSV23 ≥1 year after PCV13 (for immunocompetent) or ≥8 weeks after PCV13 (for high-risk) 1

If Previously Received Both PCV13 and PPSV23

• If PPSV23 was given at age ≥65: Shared decision-making for additional PCV20 dose ≥5 years after last vaccine 1
• If PPSV23 was given before age 65: Give PPSV23 at appropriate intervals based on risk status 1

Key Changes from 2019 Guidelines

The 2019 ACIP guidelines marked a major shift by eliminating routine PCV13 recommendation for all adults ≥65 years, instead recommending it only through shared clinical decision-making for immunocompetent adults 2. This change occurred because:

• Pediatric PCV13 vaccination created substantial indirect (herd) protection for older adults
• PCV13-type disease incidence dropped to historically low levels
• Population-level impact of adult PCV13 vaccination was minimal 2
• Cost-effectiveness ratios became unfavorable ($200,000-$560,000 per QALY vs. $65,000 in 2014) 2

However, PPSV23 remained universally recommended for all adults ≥65 years because it covers 11 additional serotypes accounting for 32-37% of invasive pneumococcal disease in this age group 2.

The 2023 update simplified recommendations by introducing PCV20 and PCV15 as alternatives, eliminating the complexity of the shared decision-making approach for PCV13.

Critical Timing Intervals

Never co-administer PCV and PPSV23 on the same day 2.

Interval rules:

• Immunocompetent adults: ≥1 year between any pneumococcal vaccines 1, 2
• Immunocompromised adults: ≥8 weeks between PCV and PPSV23 1, 2
• If PPSV23 given before age 65: Give another PPSV23 dose at age ≥65, but ≥5 years after previous PPSV23 2
• No additional PPSV23 doses after the dose given at age ≥65 2

Common Pitfalls to Avoid

1. Wrong vaccine order: Always give conjugate vaccine (PCV20, PCV15, or PCV13) before PPSV23 when both are needed 2. Conjugate vaccines prime the immune system more effectively.

2. Incorrect intervals: Using 8-week intervals for immunocompetent patients or 1-year intervals for immunocompromised patients reduces vaccine effectiveness 1.

3. Forgetting previous PPSV23: Adults who received PPSV23 before age 65 need another dose at age ≥65, but must wait ≥5 years 2.

4. Over-vaccination: No more than 2 lifetime doses of PPSV23 are recommended; additional doses provide no benefit and may cause hyporesponsiveness 2.

Immunogenicity Evidence

PCV13 demonstrated superior immune responses compared to PPSV23 in multiple trials, with higher opsonophagocytic antibody titers for most serotypes 3. For serotype 6A (unique to PCV13), 88.5% of vaccine-naive adults aged 60-64 achieved ≥4-fold antibody increases with PCV13 versus only 49.3% with PPSV23 3.

PCV13 induces durable IgA and complement-mediated responses that persist for at least 42 months, suggesting mucosal immunity that PPSV23 cannot provide 4. This mechanistic advantage supports the conjugate-first approach, though population-level benefits remain modest due to herd immunity 2.